Matches in SemOpenAlex for { <https://semopenalex.org/work/W4301352562> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W4301352562 endingPage "45" @default.
- W4301352562 startingPage "33" @default.
- W4301352562 abstract "Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both.Cross-talk between the rennin-angiotensin system (RAS) and insulin signaling has been demonstrated. The rennin angiotensin system (RAS) may regulatepancreatic islet blood flow, oxygen tension, and islet (pro) insulin biosynthesis.The present study was designed to evaluate the effect of low doses captopril and losartan, as adjunct treatment in uncontrolled type 2 DM patients treated with oral hypoglycemic agents alone.This double-blind placebo-controlled clinical trial was conducted on 75 patients with uncontrolled type 2 diabetes mellitus; they are randomized into three groups:Group A: includes (25) patients treated with placebo formula containing lactose only in addition to glibenclamide (10 mg/kg) for 4 months; group B: includes(25) patients treated with 12.5 mg captopril given once daily at bed time, for 4 months; group C: includes (25) patients treated with 25 mg losartan given as asingle daily dose at bed time for 4 months; all patients take the test drugs in addition to the routinely administered oral hypoglycemic drug (glibenclamide 10mg/kg). After 12 hours fasting, blood samples were collected from all patients to measure fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), Cpeptide, triglyceride (TG), total cholesterol, low density lipoprotein (LDL-c), high density lipoprotein (HDL-c), serum urea and creatinine, alanine transaminase, aspartate transaminase, alkaline phosphatase (ALP) and gamma glutamine transferees (GGT), and urine samples were obtained for assessment ofmicroalbuminuria (MAU), before starting drug treatment (as zero time sample) and then after 4 months of treatment to follow the changes in the studiedparameters.Adjuvant use of low doses of captopril or losartan with the currently used oral hypoglycemic agents (glibenclamide) results in significant reduction in FPG and HbA1c levels associated with increase in C-peptide level compared to those treated with the oral hypoglycemic agents and placebo; additionally, lipid profile, MAU, renal and liver functions were significantly improved after 4 months of treatment.Inhibition of RAS by ACEIs or AT1 antagonists (ARBs) increases insulin sensitivity and improves insulin secretion, where treatment of poorly controlled type 2 DM patients with captopril or losartan resulted in improving the response of target tissues to glibenclamide." @default.
- W4301352562 created "2022-10-05" @default.
- W4301352562 creator A5024607041 @default.
- W4301352562 creator A5034585930 @default.
- W4301352562 creator A5084135198 @default.
- W4301352562 creator A5087158404 @default.
- W4301352562 date "2010-12-01" @default.
- W4301352562 modified "2023-09-25" @default.
- W4301352562 title "Effects of Low Doses of Captopril or Losartan in Improving Glycemic Control by Oral Hypoglycemic Agents in Type 2 DM Patients" @default.
- W4301352562 doi "https://doi.org/10.32947/ajps.v8i2.331" @default.
- W4301352562 hasPublicationYear "2010" @default.
- W4301352562 type Work @default.
- W4301352562 citedByCount "0" @default.
- W4301352562 crossrefType "journal-article" @default.
- W4301352562 hasAuthorship W4301352562A5024607041 @default.
- W4301352562 hasAuthorship W4301352562A5034585930 @default.
- W4301352562 hasAuthorship W4301352562A5084135198 @default.
- W4301352562 hasAuthorship W4301352562A5087158404 @default.
- W4301352562 hasBestOaLocation W43013525621 @default.
- W4301352562 hasConcept C126322002 @default.
- W4301352562 hasConcept C134018914 @default.
- W4301352562 hasConcept C2777180221 @default.
- W4301352562 hasConcept C2777538456 @default.
- W4301352562 hasConcept C2779306644 @default.
- W4301352562 hasConcept C2779479957 @default.
- W4301352562 hasConcept C2780288358 @default.
- W4301352562 hasConcept C2780306776 @default.
- W4301352562 hasConcept C2780473172 @default.
- W4301352562 hasConcept C2908929049 @default.
- W4301352562 hasConcept C555293320 @default.
- W4301352562 hasConcept C71924100 @default.
- W4301352562 hasConcept C84393581 @default.
- W4301352562 hasConceptScore W4301352562C126322002 @default.
- W4301352562 hasConceptScore W4301352562C134018914 @default.
- W4301352562 hasConceptScore W4301352562C2777180221 @default.
- W4301352562 hasConceptScore W4301352562C2777538456 @default.
- W4301352562 hasConceptScore W4301352562C2779306644 @default.
- W4301352562 hasConceptScore W4301352562C2779479957 @default.
- W4301352562 hasConceptScore W4301352562C2780288358 @default.
- W4301352562 hasConceptScore W4301352562C2780306776 @default.
- W4301352562 hasConceptScore W4301352562C2780473172 @default.
- W4301352562 hasConceptScore W4301352562C2908929049 @default.
- W4301352562 hasConceptScore W4301352562C555293320 @default.
- W4301352562 hasConceptScore W4301352562C71924100 @default.
- W4301352562 hasConceptScore W4301352562C84393581 @default.
- W4301352562 hasIssue "2" @default.
- W4301352562 hasLocation W43013525621 @default.
- W4301352562 hasOpenAccess W4301352562 @default.
- W4301352562 hasPrimaryLocation W43013525621 @default.
- W4301352562 hasRelatedWork W1976670837 @default.
- W4301352562 hasRelatedWork W1983641721 @default.
- W4301352562 hasRelatedWork W2008378339 @default.
- W4301352562 hasRelatedWork W2022647335 @default.
- W4301352562 hasRelatedWork W2026226896 @default.
- W4301352562 hasRelatedWork W2066345847 @default.
- W4301352562 hasRelatedWork W2070539845 @default.
- W4301352562 hasRelatedWork W2089387278 @default.
- W4301352562 hasRelatedWork W2095179743 @default.
- W4301352562 hasRelatedWork W3174801343 @default.
- W4301352562 hasVolume "8" @default.
- W4301352562 isParatext "false" @default.
- W4301352562 isRetracted "false" @default.
- W4301352562 workType "article" @default.